Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD3 known ✓ | O94806 | 8/20 | 0.55 |
| ▸ | PRKCG known ✓ | P05129 | 8/20 | 0.55 |
| ▸ | PRKCB known ✓ | P05771 | 8/20 | 0.55 |
| ▸ | PRKCA known ✓ | P17252 | 8/20 | 0.55 |
| ▸ | PRKCH known ✓ | P24723 | 8/20 | 0.55 |
| ▸ | PRKCI known ✓ | P41743 | 8/20 | 0.55 |
| ▸ | PRKCE known ✓ | Q02156 | 8/20 | 0.55 |
| ▸ | PRKCQ known ✓ | Q04759 | 8/20 | 0.55 |
| ▸ | PRKCZ known ✓ | Q05513 | 8/20 | 0.55 |
| ▸ | PRKCD known ✓ | Q05655 | 8/20 | 0.55 |
| ▸ | PRKD1 known ✓ | Q15139 | 8/20 | 0.55 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.54 |
| ▸ | ROCK2 known ✓ | O75116 | 5/20 | 0.51 |
| ▸ | ROCK1 known ✓ | Q13464 | 5/20 | 0.51 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.49 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.49 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.49 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.49 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.49 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9477757 | 1.00 | LMNA (0.57) | LMNAMEN1KMT2ASMN1; SMN2PMP22 | |
| SCHEMBL117745 | 0.98 | CYP3A4 (0.56) | LMNAMEN1KMT2ASMN1; SMN2PMP22 | |
| SCHEMBL29696494 | 0.98 | CYP3A4 (0.56) | LMNAMEN1KMT2ASMN1; SMN2PMP22 | |
| Fluoride SCHEMBL28263329 | 0.97 | CYP3A4 (0.55) | LMNAMEN1KMT2ASMN1; SMN2PMP22 | |
| Sulfuric Acid SCHEMBL29120407 | 0.97 | CYP3A4 (0.55) | LMNAMEN1KMT2ASMN1; SMN2PMP22 | |
| Hydrochloric Acid SCHEMBL27788261 | 0.86 | TNF (0.45) | LMNAMEN1KMT2ASMN1; SMN2PMP22 | |
| SCHEMBL26422606 | 0.84 | TNF (0.46) | LMNAMEN1KMT2ASMN1; SMN2PMP22 | |
| Hydrochloric Acid SCHEMBL28291160 | 0.84 | LMNA (0.49) | LMNAMEN1KMT2ASMN1; SMN2PMP22 | |
| SCHEMBL6967362 | 0.84 | CYP3A4 (0.59) | LMNAMEN1KMT2ASMN1; SMN2PMP22 | |
| Hydrochloric Acid SCHEMBL29748700 | 0.83 | LMNA (0.61) | LMNAMEN1KMT2ASMN1; SMN2PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-58121279-A | — | — | None | — | — | JP | disclosed |
| JP-58121278-A | — | — | None | — | — | JP | disclosed |
| JP-7277979-A | — | — | None | — | — | JP | disclosed |
| JP-10087491-A | — | — | None | — | — | JP | disclosed |
| JP-57156463-A | — | — | None | — | — | JP | disclosed |
| US-20240287027-A1 | PREPARATION METHOD FOR COMPOUND FASUDIL HYDROCHLORIDE | EAST CHINA UNIVERSITY OF SCIENCE & TECHNOLOGY (CN) | 2024-08-29 | — | — | US | disclosed |
| CN-113372329-B | Preparation method of fasudil hydrochloride compound | 华东理工大学 | 2022-10-18 | — | — | CN | disclosed |
| CN-113372329-A | Preparation method of fasudil hydrochloride compound | 华东理工大学 | 2021-09-10 | — | — | CN | disclosed |
| CN-109574992-A | A kind of preparation method of Fasudic hydrochloride | 河南润弘制药股份有限公司 | 2019-04-05 | — | — | CN | disclosed |
| CN-109374811-A | The detection method of 5- isoquinolin sulfonic acid in a kind of Fasudic hydrochloride | 昆药集团股份有限公司 | 2019-02-22 | — | — | CN | disclosed |
| CN-1929847-A | Fasudil-containing preparation and method for improving stability thereof | ASAHI KASEI PHARMA CORP (JP) | 2007-03-14 | — | — | CN | disclosed |
| CN-1354663-A | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO (US) | 2002-06-19 | — | — | CN | disclosed |
| US-5747507-A | MYOCARDIAL DISEASE | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1998-05-05 | — | — | US | disclosed |
| JP-H1087491-A | TRANSCRIPTION CONTROL FACTOR INHIBITOR | ASAHI CHEM IND CO LTD | 1998-04-07 | — | — | JP | disclosed |
| JP-H07277979-A | THERAPEUTIC OR PREVENTIVE AGENT FOR HYPERVISCOSITY SYNDROME | ASAHI CHEM IND CO LTD | 1995-10-24 | — | — | JP | disclosed |
| EP-0654266-A1 | CARDIAC PROTECTIVE | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1995-05-24 | — | — | EP | disclosed |
| US-5298503-A | Cardiovascular | ADIR ET COMPAGNIE (FR) | 1994-03-29 | — | — | US | disclosed |
| JP-S58121279-A | ISOQUINOLINESULFONYL COMPOUND | ASAHI CHEM IND CO LTD | 1983-07-19 | — | — | JP | disclosed |
| JP-S58121278-A | ISOQUINOLINESULFONIC ACID AMIDE DERIVATIVE | ASAHI CHEM IND CO LTD | 1983-07-19 | — | — | JP | disclosed |
| JP-S57156463-A | ISOQUINOLINE DERIVATIVE | ASAHI CHEM IND CO LTD | 1982-09-27 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287027-A1 | PREPARATION METHOD FOR COMPOUND FASUDIL HYDROCHLORIDE | BAD, CASP5, REN | PRKD3 1290/4885PRKCG 848/4885PRKCB 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.